Actively Recruiting
Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
Led by National Taiwan University Hospital · Updated on 2026-05-08
990
Participants Needed
1
Research Sites
351 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to compare the efficacy and safety of a bismuth-supplemented 14-day vonoprazan-based dual therapy ( triple therapy) versus a 14-day vonoprazan-based dual therapy without bismuth for first-line H. pylori eradication. Furthermore, the investigators will investigate the impact of these eradication regimens on the gut microbiota, the development of antibiotic resistance, and changes in metabolic syndrome indicators pre- and post-treatment.
CONDITIONS
Official Title
Effect of Bismuth Add-on to Dual Therapy for Helicobacter Pylori Eradication
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infected with Helicobacter pylori and have not had eradication therapy before
- Willing to receive first-line eradication therapy
- At least 20 years old
You will not qualify if you...
- History of stomach removal surgery (gastrectomy)
- Unsuitable for study drugs due to allergy or severe side effects
- Pregnant or breastfeeding women
- Severe acute or chronic diseases such as renal failure, liver cirrhosis, or incurable cancers
- Chronic hepatitis with AST or ALT levels over 100 U/L
- Unwilling to follow the treatment plan or sign consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan
Actively Recruiting
Research Team
M
Mei-Jyh Chen, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here